Euroopan unioni - suomi - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - rokotteet - a (h1n1) v 2009 -viruksen aiheuttaman influenssan profylaksia. celvapan tulee käyttää virallisen ohjeistuksen mukaisesti.

Suomi - suomi - Ecolab

ecolab deutschland gmbh -

Euroopan unioni - suomi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - deksametasoni - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex on tarkoitettu aikuisille potilaille, joilla on silmänpohjan turvotus seuraavat joko haara verkkokalvon-laskimon tukos (brvo) tai verkkokalvon-laskimotukos (crvo). ozurdex on tarkoitettu aikuisille potilaille, joilla on tulehdus taka-segmentin silmän esittelee sekä tartunnallisia uveiitti. ozurdex on tarkoitettu aikuisille potilaille, joilla on näkövamma, koska diabeettinen makulaturvotus (dme), jotka ovat pseudofakiapotilailla tai jotka katsotaan riittävän herkkä, tai sopimaton ei-kortikosteroidihoito.

Suomi - suomi - Fimea (Suomen lääkevirasto)

nanotherapeutics bohumil, s.r.o. - influenssa a h1n1-virus, pinta-antigeeni, inaktivoitu,influenssa a-viruksen h3n2, pinta-antigeeni, inaktivoitu,influenssa b-virus, pinta-antigeeni, inaktivoitu - injektioneste, suspensio, esitäytetty ruisku - 15 mikrog ha / 0.5 ml - influenssarokote, puhdistettu antigeeni

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna on tarkoitettu hoito aikuis-ja lapsipotilailla, joilla on näön menetys johtuu perinnöllinen verkkokalvon dystrofia aiheuttama vahvisti biallelic rpe65-mutaatioita ja jotka ovat riittävän kannattavia verkkokalvon soluja.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombosytopeeninen, idiopaattinen - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiset kasvaimet - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Euroopan unioni - suomi - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - essentiaalisen hypertension hoito. imprida on tarkoitettu potilaille, joiden verenpaine ei laske riittävästi yksinomaan amlodipiinilla tai valsartaanilla.